- Home
- CLLS vs INGN Comparison
CLLS vs INGN Comparison
Compare CLLS & INGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- INGN
- Stock Information
- Founded
- CLLS 1999
- INGN 2001
- Country
- CLLS France
- INGN United States
- Employees
- CLLS N/A
- INGN N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- INGN Industrial Specialties
- Sector
- CLLS Health Care
- INGN Health Care
- Exchange
- CLLS Nasdaq
- INGN Nasdaq
- Market Cap
- CLLS 143.4M
- INGN N/A
- IPO Year
- CLLS 2007
- INGN 2014
- Fundamental
- Price
- CLLS $1.58
- INGN $7.49
- Analyst Decision
- CLLS Buy
- INGN Strong Buy
- Analyst Count
- CLLS 1
- INGN 3
- Target Price
- CLLS $4.00
- INGN $11.00
- AVG Volume (30 Days)
- CLLS 54.7K
- INGN 205.2K
- Earning Date
- CLLS 08-05-2025
- INGN 08-05-2025
- Dividend Yield
- CLLS N/A
- INGN N/A
- EPS Growth
- CLLS N/A
- INGN N/A
- EPS
- CLLS N/A
- INGN N/A
- Revenue
- CLLS $54,747,000.00
- INGN $339,960,000.00
- Revenue This Year
- CLLS $48.52
- INGN $7.46
- Revenue Next Year
- CLLS $5.17
- INGN $6.03
- P/E Ratio
- CLLS N/A
- INGN N/A
- Revenue Growth
- CLLS 351.26
- INGN 5.73
- 52 Week Low
- CLLS $1.10
- INGN $5.70
- 52 Week High
- CLLS $2.43
- INGN $13.33
- Technical
- Relative Strength Index (RSI)
- CLLS 64.58
- INGN 68.13
- Support Level
- CLLS $1.41
- INGN $6.86
- Resistance Level
- CLLS $1.65
- INGN $7.30
- Average True Range (ATR)
- CLLS 0.10
- INGN 0.33
- MACD
- CLLS 0.03
- INGN 0.09
- Stochastic Oscillator
- CLLS 93.81
- INGN 92.54
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.